ST2 and copeptine – modern biomarkers for monitoring the effectiveness of treatment of decompensated heart failure in patients after acute myocardial infarction

Keywords: myocardial infarction, decompensated heart failure, ST2, copeptin succinic acid, arginine preparations

Abstract

The aim of the study was to increase the efficiency of diagnostic methods to find means to improve the treatment of patients with decompensated heart failure in the post-infarction period.

Materials and methods. This study is based on an examination of 120 patients with decompensated HF (60 patients with STEMI and 60 with non-STEMI). Patients with previous STEMI complicated by decompensated heart failure were divided into groups, depending on their treatment. The studied groups were homogeneous in terms of age, sex, the severity of the course of the disease, duration of the post-infarction period, and the presence of clinical manifestations of decompensation. The patients were observed on the first day after hospitalization, after 1 and 2 months after treatment. Copeptin serum levels were assayed using the EK 065-32, EIA Copeptine kit (RayBiotech, Inc., USA). ST-2 in blood serum was determined with the help of the Presage ST-2 kit (Critical Diagnostics, USA). The level of ST2 was determined in ng/ml.

Results. We analysed the effect of therapy on the level of ST2 in the blood serum of examined patients with STEMI and non-STEMI complicated by decompensated heart failure. All the treatment regimens we proposed led to a significant decrease in the level of this peptide in blood serum after the end of the treatment. In patients of group I who received basic therapy drugs, the average ST2 concentration was (49.47±1.77) ng/ml before treatment. After 1 and 2 months of therapy, it was (44.92±1.22) ng/ml and (41.67±1.18) ng/ml, respectively (p˂0.05). The patients with decompensated heart failure after non-STEMI from group I had a copeptin level of (18.13±0.10) pg/ml before treatment and probably decreased to levels of (16.29±0.15) pg/ml and (15.09±0.14) pg/ml after 1 and 2 months under the influence standard therapy.

Conclusions. We found the dependence of copeptin and ST2 levels on decompensated HF in the early and late post-infarction periods. It was established that the use of the therapy with a combination of the studied drugs led to a more intense decrease in serum copeptin, compared to therapy with succinic acid, arginine drugs, and standard therapy (p˂0.05). Using a differentiated treatment algorithm for patients with decompensated heart failure in the post-infarction period, copeptin and ST2 in blood serum increases the effectiveness of treatment and prevents complications.

Downloads

Download data is not yet available.

Author Biographies

Khrystyna Levandovska, Ivano-Frankivsk National Medical University

Department of Internal Medicine No. 2 and Nursing

Ihor Vakaliuk, Ivano-Frankivsk National Medical University

Department of Internal Medicine No. 2 and Nursing

Natalia Tymochko, Ivano-Frankivsk National Medical University

Department of Internal Medicine No. 2 and Nursing

References

Saleh, M., Ambrose, J. A. (2018). Understanding myocardial infarction. F1000Research, 7, 1378. doi: https://doi.org/10.12688/f1000research.15096.1

Zeymer, U. (2019). Hat der Patient einen Herzinfarkt? MMW – Fortschritte Der Medizin, 161 (4), 34–36. doi: https://doi.org/10.1007/s15006-019-0223-3

Jenča, D., Melenovský, V., Stehlik, J., Staněk, V., Kettner, J., Kautzner, J., Adámková, V., Wohlfahrt, P. (2020). Heart failure after myocardial infarction: incidence and predictors. ESC Heart Failure, 8 (1), 222–237. doi: https://doi.org/10.1002/ehf2.13144

Arrigo, M., Jessup, M., Mullens, W., Reza, N., Shah, A. M., Sliwa, K., Mebazaa, A. (2020). Acute heart failure. Nature Reviews Disease Primers, 6 (1). doi: https://doi.org/10.1038/s41572-020-0151-7

Pfeffer, M. A., Shah, A. M., Borlaug, B. A. (2022). AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Heart Failure With Preserved Ejection Fraction In Perspective. Circulation Research, 124 (11), 1598–1617.

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M. et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145 (18), e895–e1032. doi: https://doi.org/10.1161/cir.0000000000001063

Sinnenberg, L., Givertz, M. M. (2020). Acute heart failure. Trends in Cardiovascular Medicine, 30 (2), 104–112. doi: https://doi.org/10.1016/j.tcm.2019.03.007

Snipelisky, D., Chaudhry, S.-P., Stewart, G. C. (2019). The Many Faces of Heart Failure. Cardiac Electrophysiology Clinics, 11 (1), 11–20. doi: https://doi.org/10.1016/j.ccep.2018.11.001

Tomasoni, D., Adamo, M., Lombardi, C. M., Metra, M. (2019). Highlights in heart failure. ESC Heart Failure, 6 (6), 1105–1127. doi: https://doi.org/10.1002/ehf2.12555

Raj, L., Maidman, S. D., Adhyaru, B. B. (2019). Inpatient management of acute decompensated heart failure. Postgraduate Medical Journal, 96 (1131), 33–42. doi: https://doi.org/10.1136/postgradmedj-2019-136742

Savvoulidis, P., Snider, J. V., Rawal, S., Morris, A. A., Butler, J., Georgiopoulou, V. V., Kalogeropoulos, A. P. (2020). Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. International Journal of Cardiology, 304, 116–121. doi: https://doi.org/10.1016/j.ijcard.2019.11.002

Coronado, M. J., Bruno, K. A., Blauwet, L. A., Tschöpe, C., Cunningham, M. W., Pankuweit, S. et al. (2019). Elevated Sera sST2 Is Associated With Heart Failure in Men ≤50 Years Old With Myocarditis. Journal of the American Heart Association, 8 (2). doi: https://doi.org/10.1161/jaha.118.008968

Vianello, E., Dozio, E., Bandera, F., Schmitz, G., Nebuloni, M., Longhi, E. et al. (2019). Dysfunctional EAT thickness may promote maladaptive heart remodeling in CVD patients through the ST2-IL33 system, directly related to EPAC protein expression. Scientific Reports, 9 (1). doi: https://doi.org/10.1038/s41598-019-46676-w

Meijers, W. C., Bayes‐Genis, A., Mebazaa, A., Bauersachs, J., Cleland, J. G. F., Coats, A. J. S. et al. (2021). Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). European Journal of Heart Failure, 23 (10), 1610–1632. doi: https://doi.org/10.1002/ejhf.2346

Sardu, C., Marfella, R., Santamaria, M., Papini, S., Parisi, Q., Sacra, C., Colaprete, D. et al. (2018). Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome. Frontiers in Physiology, 9. doi: https://doi.org/10.3389/fphys.2018.00758

Michalska-Kasiczak, M., Bielecka-Dabrowa, A., von Haehling, S., Anker, S. D., Rysz, J., Banach, M. (2018). Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Archives of Medical Science, 14 (4), 890–909. doi: https://doi.org/10.5114/aoms.2018.76279

Mu, D., Cheng, J., Qiu, L., Cheng, X. (2022). Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 9. doi: https://doi.org/10.3389/fcvm.2022.901990

Gansevoort, R. T., van Gastel, M. D. A., Chapman, A. B., Blais, J. D., Czerwiec, F. S., Higashihara, E. et al. (2019). Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney International, 96 (1), 159–169. doi: https://doi.org/10.1016/j.kint.2018.11.044

Velho, G., Ragot, S., El Boustany, R., Saulnier, P.-J., Fraty, M., Mohammedi, K. et al. (2018). Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. Cardiovascular Diabetology, 17 (1). doi: https://doi.org/10.1186/s12933-018-0753-5

Go, S., Kim, S., Son, H.-E., Ryu, J.-Y., Yang, H., Choi, S. R. et al. (2021). Association between copeptin levels and treatment responses to hypertonic saline infusion in patients with symptomatic hyponatremia: a prospective cohort study. Kidney Research and Clinical Practice, 40 (3), 371–382. doi: https://doi.org/10.23876/j.krcp.20.233

Voloshyna, L. O. (2016). Evaluation of the effectiveness of the use of L-arginine aspartate in the complex treatment of patients with osteoarthritis with a high level of comorbidity and cardiovascular risk. Ukrainian therapeutic journal, 4, 63–70.

Berezin, A. E. (2015). Biological markers in diagnostics, predicting and evaluating the effectiveness of therapy for heart failure from saving and reduced contractile function. Heart failure, 2, 16–27.

Tashchuk, V. K., Ivanchuk, P. R., Tashchuk, M. V., Polyanska, O. S., Amelina, T. M., Makoviychuk, I. O. et al. (2017). Quantitative evaluation of electrocardiogram in comparison of cardioprotection efficiency in acute myocardial infarction. Bukovinian Medical Herald, 21 (2 (82)), 94–99. doi: https://doi.org/10.24061/2413-0737.xxi.2.82.1.2017.20

Baumann, P., Gotta, V., Atkinson, A., Deisenberg, M., Hersberger, M., Roggia, A. et al. (2022). Copeptin Release in Arterial Hypotension and Its Association with Severity of Disease in Critically Ill Children. Children, 9 (6), 794. doi: https://doi.org/10.3390/children9060794

Düring, J., Annborn, M., Cronberg, T., Dankiewicz, J., Devaux, Y., Hassager, C. et al. (2020). Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial. Critical Care, 24 (1). doi: https://doi.org/10.1186/s13054-020-02904-8

Crespo-Leiro, M. G., Metra, M., Lund, L. H., Milicic, D., Costanzo, M. R., Filippatos, G. et al. (2018). Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20 (11), 1505–1535. doi: https://doi.org/10.1002/ejhf.1236

Xanthakis, V., Enserro, D. M., Larson, M. G., Wollert, K. C., Januzzi, J. L., Levy, D. et al. (2016). Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC: Heart Failure, 4 (10), 808–815. doi: https://doi.org/10.1016/j.jchf.2016.05.001

Hummel, Y. M., Liu, L. C. Y., Lam, C. S. P., Fonseca-Munoz, D. F., Damman, K., Rienstra, M. et al. (2017). Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 19 (12), 1651–1660. doi: https://doi.org/10.1002/ejhf.957

Stojcevski, B., Celic, V., Navarin, S., Pencic, B., Majstorovic, A., Sljivic, A. et al. (2015). The use of discharge haemoglobin and NT-proBNP to improve short and long-term outcome prediction in patients with acute heart failure. European Heart Journal: Acute Cardiovascular Care, 6 (8), 676–684. doi: https://doi.org/10.1177/2048872615585521

Zhang, P., Wu, X., Li, G., Sun, H., Shi, J. (2017). Prognostic role of copeptin with all-cause mortality after heart failure: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 13, 49–58. doi: https://doi.org/10.2147/tcrm.s124689


👁 124
⬇ 119
Published
2022-09-30
How to Cite
Levandovska, K., Vakaliuk, I., & Tymochko, N. (2022). ST2 and copeptine – modern biomarkers for monitoring the effectiveness of treatment of decompensated heart failure in patients after acute myocardial infarction. EUREKA: Health Sciences, (5), 30-38. https://doi.org/10.21303/2504-5679.2022.002683
Section
Medicine and Dentistry